



NAVA/SECTL/88/2026-27

June 22, 2026

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI – 400 051
NSE Symbol: 'NAVA'

Dept. of Corp. Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Scrip Code: '513023' / 'NAVA'

Dear Sir/ Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR").

--o0o--

This is to inform you that the Board of Directors of the Company, at its meeting held today, i.e., June 22, 2026, has, inter alia, considered and approved the proposed amalgamation of Nava Healthcare Pte. Ltd., a wholly owned subsidiary of the Company, with Nava Global Pte. Ltd., another wholly owned subsidiary of the Company, subject to the requisite approvals from the relevant regulatory authorities and compliance with the applicable laws of Singapore.

The amalgamation is proposed as part of an internal reorganization of the Company's subsidiary structure and is subject to such terms and conditions as may be prescribed by the relevant regulations and authorities.

Details as required under SEBI circular no. **SEBI/HO/CFD/PoD2/CIR/P/0155** dated November 11, 2024, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are annexed herewith

This document is made available on the website of the Company at <https://www.navalimited.com/investors/stock-exchange-disclosures/disclosures/>

Kindly take the same on record and acknowledge the receipt.

Thanking You,
Yours faithfully,
for NAVA LIMITED

VSN Raju
Company Secretary
& Vice President

Encl: as above

ANNEXURE - 1

Amalgamation/ Merger:

a)	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;	<p>Nava Global Pte. Ltd (Reg. no. 200409999D) (NGPL) and Nava Healthcare Pte. Ltd (Reg. no. 201726052H) (NHPL) are investment holding companies of Nava (as per financials set out below), operating in Singapore.</p> <p style="text-align: right;">As at 31.03.2026</p> <table border="1" data-bbox="711 562 1417 737"> <thead> <tr> <th>Financial data</th> <th>NGPL</th> <th>NHPL</th> </tr> </thead> <tbody> <tr> <td>Income</td> <td>Rs. 1,05,914 lakhs US\$ 120 mn</td> <td>Rs. 279 lakhs US\$ 0.3 mn</td> </tr> <tr> <td>Networth</td> <td>Rs. 2,72,988 lakhs (US\$ 288.4 mn)</td> <td>Rs. 7,468 lakhs (US\$ 7.9 mn)</td> </tr> </tbody> </table>	Financial data	NGPL	NHPL	Income	Rs. 1,05,914 lakhs US\$ 120 mn	Rs. 279 lakhs US\$ 0.3 mn	Networth	Rs. 2,72,988 lakhs (US\$ 288.4 mn)	Rs. 7,468 lakhs (US\$ 7.9 mn)
Financial data	NGPL	NHPL									
Income	Rs. 1,05,914 lakhs US\$ 120 mn	Rs. 279 lakhs US\$ 0.3 mn									
Networth	Rs. 2,72,988 lakhs (US\$ 288.4 mn)	Rs. 7,468 lakhs (US\$ 7.9 mn)									
b)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Yes, the transaction is a related party transaction and is between the two wholly owned subsidiaries (in Singapore) of the Company. NHPL is proposed to be amalgamated into NGPL in compliance with applicable laws.									
c)	Area of business of the entity(ies)	NGPL holds downstream investments in Energy, Mining and Metals while NHPL holds downstream investments in healthcare trading and services.									
d)	Rationale for amalgamation/ merger	<p>NGPL has established investments across the energy, minerals and metals sectors and plans to further diversify its investment portfolio across businesses and geographies, leveraging its long-standing presence in the APAC region.</p> <p>NHPL, through its subsidiaries in Singapore and Malaysia, has investments in the trading of niche women's healthcare and lifestyle improvement products.</p> <p>Healthcare business, hitherto pursued by NHPL attained certain traction in Malaysia and Singapore, further growth of which is however incumbent upon focused approach and other value-added offerings which will ensure sustained positive cash flows. This requires strategic partnership with experienced professional concerns to target potential upsides.</p> <p>Accordingly, NGPL, post amalgamation of NHPL, will pursue a strategic business restructuring including joint ventures to bring in other medical offerings, aside from continuing the existing trading business of the niche products in South East Asia. This is expected to ensure continuity of the existing business, facilitate expansion into value-added healthcare services and other growth opportunities for which potential exists in South East Asia. NGPL, will continue to</p>									

		<p>be vigilant to emerging opportunities in South East Asia in this sector.</p> <p>The proposed amalgamation of NHPL with NGPL will consolidate the Group's investments (other than commercial agriculture and O&M services) under one platform. NGPL will oversee the restructured healthcare investment under a simplified holding structure, as part of the Group's broader investment diversification in the pursuit of long-term value for stakeholders.</p>
e)	In case of cash consideration – amount or otherwise share exchange ratio	Since both the Companies involved in amalgamation are wholly owned subsidiaries of Nava Limited, Nava's holding in NHPL will be cancelled and, NGPL issues new shares to Nava after amalgamation.
f)	Brief details of change in shareholding pattern (if any) of listed entity	The proposed amalgamation is between two wholly owned subsidiaries of the Company and, therefore, will not result in any change in the shareholding pattern of the Company.